Profitelligence Profitelligence · Filing Ledger Open GILD research →

Form 8-K · Current Report · Filed 2026-05-07

Gilead Sciences Reports Strong Q1 2026 Results and Updates Guidance

Gilead Sciences, Inc. announced its first quarter 2026 financial results, showing an 8% year-over-year growth in product sales excluding Veklury, driven by a 10% increase in HIV product sales and a 37% rise in Trodelvy sales. The company reported total revenues of $7.0 billion, a 4% increase from the same period in 2025. Gilead also declared a quarterly dividend of $0.82 per share and updated its full-year 2026 guidance, reflecting its strong performance.

Filer
Gilead Sciences Inc. GILD · NASDAQ
Filed
Accession
0000882095-26-000022
CIK
0000882095
Signal
High impactHealthcare

Items reported

Item events

Reported Item

Earnings Beat General Statement Dividend Announced Raised Guidance

Market reaction

Close before filing

$136.30

Next session

-3.6%

Since filing

-4.5%

Latest close

$130.21

What happened, not what will happen — closing prices around the filing date.

Precedent

Previous filings from GILD reporting the same item, with the next session's move:

Insider tape

Within 45 days of this filing, GILD insiders reported 29 Form 4 transactions — net selling of $6.0M.

Full GILD insider history →

About Gilead Sciences Inc.

Gilead Sciences Inc. is a biopharmaceutical company that focuses on researching, developing, and commercializing innovative medicines in areas of unmet medical need. It is globally recognized for its distinguished work, particularly in the treatment of HIV, liver diseases such as hepatitis B and C, and various forms of cancer. The company's portfolio includes groundbreaking antiviral therapies and a robust pipeline of investigational drugs. Headquartered in Foster City, California, Gilead Sciences Inc. significantly contributes to the healthcare sector by extending the lives of patients with serious illnesses worldwide. Through strategic partnerships and continuous innovation, Gilead remains at the forefront of modern medicine, enhancing its role in the global pharmaceutical market.

Exchange NASDAQ Industry Drug Manufacturers - General Company website ↗

Never miss another GILD filing

Profitelligence watches EDGAR around the clock and alerts you within seconds.

Set up free alerts